(GSA) has submitted to the Office of Management and Budget (OMB) a request to review and approve an extension of a previously approved information collection requirement concerning Contract Financing.

DATES: Comments may be submitted on or before September 11, 2001.

FOR FURTHER INFORMATION CONTACT: Jeremy Olson, Acquisition Policy Division, GSA (202) 501–3221.

ADDRESSES: Comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, should be submitted to: Edward Springer, GSA Desk Officer, OMB, Room 10236, NEOB, Washington, DC 20503, and a copy to Stephanie Morris, General Services Administration (MVP), 1800 F Street, NW., Room 4035, Washington, DC 20405.

SUPPLEMENTARY INFORMATION:

A. Purpose

The General Services Administration is requesting the Office of Management and Budget (OMB) to review and approve information collection, 3090–0080, concerning Contract Financing. Offerors are required to identify whether items are foreign source end products and the dollar amount of import duty for each product.

B. Annual Reporting Burden.

Respondents: *2,000.*

Annual Responses: *2,000.*

Average Hours Per Response: *.1.*

Burden Hours: *200.*

Obtaining Copies of Proposals

A copy of this proposal may be obtained from the General Services Administration, Acquisition Policy Division (MVP), 1800 F Street, NW., Room 4035, Washington, DC 20405, or by telephoning (202) 501–4744, or by faxing your request to (202) 501–4067. Please cite OMB Control No. 3090–0080, Contract Financing, in all correspondence.

Dated: June 18, 2001.

David A. Drabkin,

Deputy Associate Administrator, Office of Acquisition Policy.

[FR Doc. 01–17611 Filed 7–12–01; 8:45 am]

BILLING CODE 6820–61–U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[Program Announcement–01126]

Enhancement of State, County or Local Public Health Departments Participation in Brownfields Decisions and Actions; Notice of Availability of Funds Amendment

A notice announcing the availability of fiscal year 2001 funds for the Enhancement of State, County or Local Public Health Departments Participation in Brownfield Decisions and Actions was published in the **Federal Register** on June 27, 2001, [Vol. 66, No. 124, page 34201]. The notice is amended as follows:

On page 34201, under B., include:

A. Eligible Applicants

Applicants will be limited to the official county, city, federally recognized tribal governments, and other local public health agencies of local communities (with the exception of Rhode Island where the State Health Department is the eligible applicant) located in the twenty-eight (28) Brownfields Showcase Communities as designated by the Environmental Protection Agency (EPA) 62 FR 44274 & 65 FR 14273). The Brownfield Showcase Communities are:

1. Baltimore, Maryland
2. Chicago, Illinois
3. Dallas, Texas
4. Denver, Colorado
5. Des Moines, Iowa
6. East Palo Alto, Califronia
7. Gila River Indian Community, Arizona
8. Glen Cove, New York
9. Houston, Texas
10. Jackson, Mississippi
11. Kansas City, Kansas & Missouri
12. Los Angeles, California
13. Lowell, Massachusetts
14. Metlakatla Indian Community, Alaska
15. Milwaukee, Wisconsin
16. Mystic Valley Development Commission (Malden, Medford, Everett), Massachusetts
17. New Bedford, Massachusetts
18. Niagara Region, New York
19. Cape Charles/Northhampton County, Virginia
20. Portland, Oregon
21. State of Rhode Island
22. Saint Louis, Missouri/East St. Louis, Illinois
23. Saint Paul, Minnesota
24. Salt Lake City, Utah
25. Seattle/King County, Washington
26. Southeast Florida (Eastward Ho!, Florida
27. Stanford, Connecticut
28. Trenton, New Jersey

Note: Title 2 of the United States Code, Chapter 26, Section 1611 states that an organization described in Section 501 (c)(4) of the Internal Revenue Code of 1986 that engages in lobbying activities is not eligible to receive Federal funds constituting an award, grant, cooperative agreement, contract, loan, or any form.

Dated: July 9, 2001.

Donna Garland,

Deputy Director, Office of Policy and External Affairs, Agency for Toxic Substances and Disease Registry.

[FR Doc. 01–17534 Filed 7–12–01; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Statement of Organization, Functions, and Delegations of Authority

Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772–76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 66 FR 29577, dated May 31, 2001) is amended to establish the Office of Compensation and Analysis within the Office of the Director, National Institute for Occupational Safety and Health.

Section C–B, Organization and Functions, is hereby amended as follows:

After the mission statement for the *Office of Administrative and Management Services (CC11), Office of the Director (CC1), National Institute for Occupational Safety and Health (CC),* insert the following:

Office of Compensation Analysis and Support (CC12). (1) Conducts a program in support of Federal rulemaking to promulgate science-based methods and guidelines mandated by the Energy Employees Occupational Illness Compensation Program Act of 2000 (''the Act'') to estimate the occupational radiation doses of claimants under the Act and evaluate the relationship between such doses and cancers incurred by the claimants; (2) develops and implements a program of science-based analysis and policymaking by which the Secretary of Health and Human Services shall consider and

issue determinations on petitions by classes of employees to be included as members of the Special Exposure Cohort established under the Act; (3) conducts a program of individual dose reconstruction to estimate and report the radiation doses of claimants under the Act; and (4) identifies and recommends the appointment of occupational physicians to physician panels to be established by the Secretary of Energy to consider the claims of workers with illnesses applying for compensation under state workers' compensation programs.

Dated: July 2, 2001.

Martha Katz,

Acting Director, Centers for Disease Control and Prevention.

[FR Doc. 01–17583 Filed 7–12–01; 8:45 am]

BILLING CODE 4160–18–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[Program Announcement No. 93612–2002A]

Fiscal Year 2002 Discretionary Announcement for The Administration for Native Americans Availability of Financial Assistance

AGENCY: Administration for Native Americans, ACF, DHHS.

ACTION: Correction.

SUMMARY: This document contains a correction to the Notice that was published in the **Federal Register** on Wednesday, June 27, 2001 (66 FR 34206). On page 34208, second column, first paragraph the following statement ''Current grantees whose grant project period extends beyond September 30, 2001'' is incorrect. The correct statement should read ''Current grantees whose grant project period extends beyond September 30, 2002''.

On page 34210, third column, second paragraph, the following statement ''Current ANA SEDS grantees whose grant project period ends on or before September 30, 2001'' is incorrect. The correct statement should read ''current ANA SEDS grantees who grant project period ends on or before September 30, 2002''.

On page 34216, second column, second paragraph, the following statement ''Applicants for new grants may not have a pending request to extend their existing grant beyond 2001'' is incorrect. The correct statement should read ''Applicants for new grants may not have a pending request to extend their existing grant beyond 2002''.

FOR FURTHER INFORMATION CONTACT: The Administration for Native Americans for referral to the appropriate contact person in ANA for programmatic questions or send an email to ANA@acf.dhhs.gov.

Dated: July 9, 2001.

Larry A. Guerrero,

Acting Commissioner, Administration for Native Americans.

[FR Doc. 01–17510 Filed 7–12–01; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 01F–0293]

Novus International, Inc.; Filing of Food Additive Petition (Animal Use)—Ethoxyquin Phosphate

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Novus International, Inc., has filed a petition proposing that the food additive regulation be amended to provide for the safe use of ethoxyquin phosphate in animal feeds.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.fda.gov/dockets/ecomments.

FOR FURTHER INFORMATION CONTACT: Michael Henry, Center for Veterinary Medicine (HFV–220), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0161, e-mail: mhenry@cvm.fda.gov.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 2244) has been filed by Novus International, Inc., 530 Maryville Centre Dr., St. Louis, MO 63141–5862. The petition proposes to amend the food additive regulations in part 573 Food Additives Permitted in Feed and Drinking Water of Animals (21 CFR part 573) for the addition of an additional salt, ethoxyquin phosphate, to be used as a preservative in yellow grease, oils, and other fats.

The agency has determined under 21 CFR 25.32(r) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: June 27, 2001.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 01–17497 Filed 7–12–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 00D–1407]

International Conference on Harmonisation; Guidance on S7A Safety Pharmacology Studies for Human Pharmaceuticals; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled ''S7A Safety Pharmacology Studies for Human Pharmaceuticals.'' The guidance was prepared under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The guidance provides a definition, general principles, and recommendations for the nonclinical safety pharmacology studies. The guidance is intended to help protect clinical trial participants and patients receiving marketed products from potential adverse effects of pharmaceuticals, while avoiding unnecessary use of animals and other resources.

DATES: This guidance is effective August 13, 2001. Submit written comments at any time.

ADDRESSES: Submit written requests for single copies of the guidance to the Division of Drug Information (HFD–240), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Single copies of the recommendations may be obtained by mail from the Office of Communication, Training and Manufacturers Assistance (HFM–40), Center for Biologics Evaluation and Research (CBER), or by calling the CBER Voice Information System at 1–800–835–4709 or 301–827–1800. Copies may be obtained from CBER's FAX Information System at 1–888–CBER–